[Immune reactions and survival of patients with ovarian carcinomas after administration of 131I-F(Ab)2 fragments of the OC 125 monoclonal antibody].
The activation of the idiotypic network seems to be a beneficial approach to the immunological therapy of ovarian cancer. In a retrospective study 62 patients with ovarian carcinoma (of which 57 could be evaluated) received 1 mg of 131J-F(Ab)2 OC 125 MAb one to five times after radical surgery and polychemotherapy. In twenty-eight patients (49%) a remarkable anti-idiotypic antibody (Ab2) response arose. The anti-idiotypic antibody (Ab2) plasma levels increased with increasing number of F(Ab)2 OC 125 MAb applications. The twenty patients (35%) who developed Ab2-concentrations > 10,000 U/ml had a significantly higher survival rate than the patients who showed weak (Ab2-concentrations < 10,000 U/ml) or no immunological response to 131J-F(Ab)2 OC 125 MAb treatment (p < 0.05).
Schmolling
J
J
Universitätsfrauenklinik, Bonn.
Wagner
U
U
Reinsberg
J
J
Biersack
H J
HJ
Krebs
D
D
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000276:immunology*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000097:blood; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; D007140:Immunoglobulin Fab Fragments; D007130:Immunoglobulin Idiotypes; D007457:Iodine Radioisotopes
Immunreaktionen und Uberlebenszeiten von Patientinnen mit Ovarialkarzinomen nach Applikation der 131J-F(Ab)2-Fragmente des OC 125 MAb.